VivoSim Labs Signs Distribution Agreements with JCBio in Korea and Tekon Biotech in China for NAMKind Toxicology Services
I'm PortAI, I can summarize articles.
VivoSim Labs Inc. has appointed JCBio as its distributor in Korea and Tekon Biotech in China for its NAMKind™ toxicology services. These agreements will enable access to human-based New Approach Methodologies (NAMs) for preclinical safety assessments, targeting a 30-day turnaround for toxicology data. This initiative aims to support faster drug development in the Asia-Pacific region.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments